By Adriano Marchese
Eye care company Alcon will offer $150 million more to buy Staar Surgical.
Under the terms of the amended agreement, Alcon will purchase all outstanding shares of Staar, for $30.75 per share in cash. This purchase price increase represents an additional $150 million approximately in equity value for stockholders.
The new price represents a total equity value of about $1.6 billion, which is about a 74% premium to Staar's 90-day volume weighted average price and a 66% premium to the closing price of Staar's stock on Aug. 4, the day before the deal was announced.
Staar stock is up 18% to $27.75 in premarket trading on Tuesday. Its shares have been slightly under pressure in the year, closing down about 3.1% at $23.54 a share on Monday. The stock is down 10% over the past 52 weeks.
Staar is a medical device company that makes implantable lenses for vision correction and eye surgery, which Alcon thinks doesn't have the scale or resources to be a profitable, high-growth standalone company.
The decision to offer more for the business followed a unfruitful "go-shop" process where Staar could freely seek out competing bids without restrictions.
At the time, Alcon had waived its matching rights and any break-up fee if there were a better offer. No offers were received and the window expired on Dec. 6.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
12-09-25 0932ET
